Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
Signal Transduction and Targeted Therapy (2022) - Comments
pubmed: 35665745  doi: 10.1038/s41392-022-00984-2  issn: 2059-3635 

Nawal Al Kaabi, Yun Kai Yang, Jing Zhang, Ke Xu, Yu Liang, Yun Kang, Ji Guo Su, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Shuai Shao, Sen Sen Yang, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud